Clinical Trials Browser

Phase 3 × Unknown × PD-L1 Positive Non-small Cell Lung Cancer × Clear all

NCT04203485 2020-05-08

Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 3 Unknown

PD-L1 Positive Non-small Cell Lung Cancer